Piper Jaffray analyst Edward Tenthoff views Alnylam Pharmaceuticals (ALNY) partnership with Regeneron (REGN) to develop RNAi therapeutics to treat nonalcoholic steatohepatitis as a positive. Alnylam's expertise in RNAi delivery to hepatocytes complements therapeutic translation of Regeneron's discovery, Tenthoff tells investors in a research note. He remains confident in FDA approval of patisiran for ATTR amyloidosis by the August 11 action date and European approval in the second half of 2018. The analyst reiterates an Overweight rating on Alnylam with a $182 price target.

Regeneron Pharmaceuticals announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA HD Injection 8 mg. The presentations are part of 14 accepted abstracts on EYLEA HD and EYLEA Injection 2 mg that will be shared at the Association for Research in Vision and Ophthalmology, ARVO, annual meeting from May 5 to 9 in Seattle. Notable podium presentations at ARVO include: One-year data from the PHOTON trial investigating EYLEA HD in diabetic macular edema patients with or without prior treatment, compared to EYLEA. Two-year results from the PULSAR trial investigating EYLEA HD in patients with wet age-related macular degeneration, compared to EYLEA, which will feature a post-hoc analysis on the correlation of key baseline disease characteristics in wAMD to dosing intervals of EYLEA HD. A PULSAR subgroup analysis evaluating visual and anatomic improvements with EYLEA HD, compared to EYLEA, based on baseline best corrected visual acuity, corneal refractive therapy, choroidal neovascularization type and race.